- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
A Fab of trastuzumab to treat HER2 overexpressing breast cancer brain metastases ; volume:13 ; number:1 ; day:15 ; month:4 ; year:2024 ; pages:1-6 ; date:12.2024
Experimental hematology & oncology ; 13, Heft 1 (15.4.2024), 1-6, 12.2024
- Creator
-
Angeli, Eurydice
Paris, Justine
Le Tilly, Olivier
Desvignes, Céline
Gapihan, Guillaume
Boquet, Didier
Pamoukdjian, Frédéric
Hamdan, Diaddin
Rigal, Marthe
Poirier, Florence
Lutomski, Didier
Azibani, Feriel
Mebazaa, Alexandre
Herbet, Amaury
Mabondzo, Aloïse
Falgarone, Géraldine
Janin, Anne
Paintaud, Gilles
Bousquet, Guilhem
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s40164-024-00513-7
- URN
-
urn:nbn:de:101:1-2406272100442.054806108156
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:45 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Angeli, Eurydice
- Paris, Justine
- Le Tilly, Olivier
- Desvignes, Céline
- Gapihan, Guillaume
- Boquet, Didier
- Pamoukdjian, Frédéric
- Hamdan, Diaddin
- Rigal, Marthe
- Poirier, Florence
- Lutomski, Didier
- Azibani, Feriel
- Mebazaa, Alexandre
- Herbet, Amaury
- Mabondzo, Aloïse
- Falgarone, Géraldine
- Janin, Anne
- Paintaud, Gilles
- Bousquet, Guilhem
- SpringerLink (Online service)
Other Objects (12)
Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
Pulsed-laser irradiation of multifunctional gold nanoshells to overcome trastuzumab resistance in HER2-overexpressing breast cancer
Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin™) in HER2-overexpressing breast cancer cells
Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials
The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody–drug conjugate–resistant HER2-overexpressing breast cancer
Systemic investigation of inetetamab in combination with small molecules to treat HER2-overexpressing breast and gastric cancers
The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity
A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy
ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer
Trastuzumab (Herceptin (R)): monoclonal antibody in the treatment of HER2/neu-overexpressing breast cancer in the metastatic and (neo)adjuvant situation
Trogocytosis-mediated expression of HER2 on immune cells may be associated with a pathological complete response to trastuzumab-based primary systemic therapy in HER2-overexpressing breast cancer patients
Recombinant monoclonal antibody trastuzumab for the treatment of metastatic breast cancer with tumors overexpressing the HER2-neu proto-oncogene : a systematic review
Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
Pulsed-laser irradiation of multifunctional gold nanoshells to overcome trastuzumab resistance in HER2-overexpressing breast cancer
Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin™) in HER2-overexpressing breast cancer cells
Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials
The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody–drug conjugate–resistant HER2-overexpressing breast cancer
Systemic investigation of inetetamab in combination with small molecules to treat HER2-overexpressing breast and gastric cancers
The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity
A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy
ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer
Trastuzumab (Herceptin (R)): monoclonal antibody in the treatment of HER2/neu-overexpressing breast cancer in the metastatic and (neo)adjuvant situation
Trogocytosis-mediated expression of HER2 on immune cells may be associated with a pathological complete response to trastuzumab-based primary systemic therapy in HER2-overexpressing breast cancer patients
Recombinant monoclonal antibody trastuzumab for the treatment of metastatic breast cancer with tumors overexpressing the HER2-neu proto-oncogene : a systematic review
Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
Pulsed-laser irradiation of multifunctional gold nanoshells to overcome trastuzumab resistance in HER2-overexpressing breast cancer
Olive oil's bitter principle reverses acquired autoresistance to trastuzumab (Herceptin™) in HER2-overexpressing breast cancer cells
Strategies to overcome trastuzumab resistance in HER2-overexpressing breast cancers: focus on new data from clinical trials
The DNA repair pathway as a therapeutic target to synergize with trastuzumab deruxtecan in HER2-targeted antibody–drug conjugate–resistant HER2-overexpressing breast cancer
Systemic investigation of inetetamab in combination with small molecules to treat HER2-overexpressing breast and gastric cancers
The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity
A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy
ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer
Trastuzumab (Herceptin (R)): monoclonal antibody in the treatment of HER2/neu-overexpressing breast cancer in the metastatic and (neo)adjuvant situation
Trogocytosis-mediated expression of HER2 on immune cells may be associated with a pathological complete response to trastuzumab-based primary systemic therapy in HER2-overexpressing breast cancer patients